Researchers at Yale School of Medicine and Columbia University Fertility Center investigate two strategies to delay menopause by targeting ovarian aging. One involves laparoscopic retrieval and cryopreservation of ovarian cortex to preserve primordial follicles; the other tests low-dose rapamycin to inhibit mTOR signaling and slow follicle depletion. These approaches aim to extend reproductive hormone function and reduce menopause-associated health risks.

Key points

• Laparoscopic retrieval and cryopreservation of ovarian cortex tissue preserves tens of thousands of primordial follicles for future transplantation.
• Periodic autografting of thawed ovarian tissue shows anticipated 60–80% follicle survival, potentially sustaining endocrine function for years.
• Weekly low-dose rapamycin administration inhibits the mTOR pathway in ovarian tissue, reducing follicular turnover and preserving ovarian reserve.
• Preclinical mouse and cell models demonstrate slowed ovarian aging and maintained egg quality following mTOR inhibition.
• Ongoing human trials (VIBRANT) assess endocrine markers, follicle counts, and menopausal onset after rapamycin treatment and tissue autografting.

Why it matters: Delaying ovarian aging could transform women’s health by extending hormonal function and reproductive capacity, potentially reducing long-term risks like osteoporosis and cardiovascular disease. These pioneering strategies may establish a new paradigm for managing endocrine aging and improve overall healthspan beyond current hormone replacement therapies.